Amneal Pharmaceuticals (AMRX) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed Amneal Pharmaceuticals (AMRX) over the past year, gaining 351.9% versus a gain of 87.5%. Over five years, AMRX leads with a +248.4% price change compared with -60.9% for SYRE. Spyre Therapeutics is the larger company by market cap ($7.86 billion vs $6.92 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRX | SYRE |
|---|---|---|
| Share price | $19.87 | $85.19 |
| Market cap | $6.92B | $7.86B |
| 1-day change | +1.12% | +6.62% |
| YTD return | +55.95% | +143.89% |
| 1-year return | +87.50% | +351.92% |
| 5-year return | +248.40% | -60.93% |
| P/E ratio (TTM) | 40.55 | — |
| Forward P/E | 16.66 | — |
| EPS (TTM) | $0.49 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.02B | $0 |
| Revenue growth (YoY) | +8.05% | — |
| Net income (latest FY) | $72.06M | $-155.20M |
| Gross margin | 36.88% | — |
| Operating margin | 13.05% | — |
| Net margin | 2.39% | — |
| 52-week high | $21.18 | $110.18 |
| 52-week low | $9.56 | $18.12 |
| Distance from 52-week high | -6.16% | -22.68% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +14.29% | +41.11% |
| Average volume | 2.29M | 1.22M |
| Shares outstanding | 348.30M | 92.29M |
| Employees | 8,700 | 125 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SYRE has outperformed AMRX by 264.4 percentage points over the past year.
About Amneal Pharmaceuticals
AMRX stock →Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,700 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Health Care · Biotechnology: Pharmaceutical Preparations · 125 employees
AMRX vs SYRE FAQ
Which is bigger, Amneal Pharmaceuticals or Spyre Therapeutics?
Spyre Therapeutics (SYRE) is larger, with a market capitalization of $7.86B compared with $6.92B for Amneal Pharmaceuticals (AMRX).
Which stock has performed better over the past year, AMRX or SYRE?
SYRE returned +351.92% over the past 12 months, compared with +87.50% for AMRX (price return, excluding dividends). Past performance does not predict future results.
Are Amneal Pharmaceuticals and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.